Mood Stabilizers - Pharmacology

1. What is the most likely effect of initiating hydrochlorothiazide on the patient's lithium therapy?
   Answer: An increase in lithium levels due to increased proximal tubular reabsorption. Thiazide diuretics, such as hydrochlorothiazide, block sodium reabsorption in the distal convoluted tubule. This leads to a compensatory increase in sodium (and lithium, which is handled similarly to sodium) reabsorption in the proximal convoluted tubule. The net effect is a reduction in lithium clearance by up to 25-50%, which can cause lithium levels to rise into the toxic range. Therefore, initiating a thiazide diuretic in a patient on lithium requires close monitoring and often a pre-emptive reduction in the lithium dose.
2. Which of the following is the most appropriate initial management step?
   Answer: Check a TSH and free T4 level to assess for lithium-induced hypothyroidism. The patient's symptoms are classic for hypothyroidism, a common long-term adverse effect of lithium therapy. Lithium interferes with thyroid hormone synthesis and release. The first step in management is to confirm the diagnosis by checking thyroid function tests (TSH and free T4). If hypothyroidism is confirmed, the standard of care is to initiate levothyroxine supplementation while continuing the lithium, especially since it is effective for her mood. Discontinuing an effective mood stabilizer is a last resort.
3. Which modification to the standard lamotrigine titration schedule is essential in this patient?
   Answer: Using a lower starting dose and a slower titration schedule due to divalproex inhibiting lamotrigine metabolism. Divalproex (valproate) is a potent inhibitor of the UDP-glucuronosyltransferase (UGT) enzymes responsible for metabolizing lamotrigine. This interaction can double the serum concentration of lamotrigine, significantly increasing the risk of Stevens-Johnson syndrome (SJS). Therefore, when co-administered with valproate, lamotrigine must be initiated at half the standard dose and titrated at a much slower rate. Valproate does not induce metabolism, there is no chelation interaction, and routine level monitoring is not the primary management strategy.
4. What is the most likely pharmacological principle responsible for the decrease in the carbamazepine level?
   Answer: Auto-induction of hepatic CYP3A4 enzymes. Carbamazepine is a potent inducer of hepatic enzymes, including CYP3A4, which is the primary enzyme responsible for its own metabolism. This process, known as auto-induction, begins after a few days of therapy and is typically complete within 3-5 weeks. The induction leads to an accelerated rate of carbamazepine clearance, resulting in a lower serum concentration despite a constant dose and good adherence. This often necessitates a dose increase after the first few weeks of therapy.
5. Which laboratory finding would be most specific for confirming a serious, known adverse effect of divalproex sodium in this patient?
   Answer: Serum lipase of 980 U/L. The patient's presentation is classic for acute pancreatitis, a known and serious adverse effect of divalproex sodium. A significantly elevated serum lipase level (typically >3 times the upper limit of normal) is the most specific laboratory marker for acute pancreatitis. While elevated liver enzymes (AST) and hyperammonemia are also associated with valproate, they do not align with the specific clinical picture of epigastric pain radiating to the back. Leukocytosis is a non-specific inflammatory marker.
6. Which of the following descriptions of the rash would be most concerning for Stevens-Johnson syndrome and warrant immediate discontinuation of the drug?
   Answer: A tender, purpuric rash on the face and trunk accompanied by fever and painful oral erosions. When you encounter questions about drug-induced rashes, especially with lamotrigine, you need to immediately assess for life-threatening conditions like Stevens-Johnson syndrome (SJS). SJS is a severe cutaneous adverse reaction that can progress to toxic epidermal necrolysis and carries significant mortality risk. Answer A correctly describes the classic presentation of SJS: tender, purpuric lesions (indicating vascular involvement and tissue damage) on the face and trunk, accompanied by systemic symptoms like fever and mucosal involvement (painful oral erosions). The combination of purpura, mucosal involvement, and systemic symptoms creates the "triad of terror" that demands immediate drug discontinuation and emergency care. Answer B describes a benign-appearing rash that's faint, non-itchy, and not spreading—characteristics that suggest a mild cutaneous reaction rather than SJS. Answer C presents a photosensitivity reaction localized to sun-exposed areas, which is unrelated to SJS and doesn't involve mucous membranes or systemic symptoms. Answer D describes a chronic, localized lesion that predates lamotrigine initiation, making it irrelevant to drug-induced pathology. The key distinguishing features of SJS are mucosal involvement (oral, ocular, or genital erosions), systemic symptoms (fever, malaise), and the morphology of skin lesions (purpuric, tender, often with epidermal detachment). Remember that lamotrigine carries a black box warning for serious rashes, particularly when titrated too rapidly or combined with valproate. Any mucosal involvement with lamotrigine-associated rash should trigger immediate discontinuation—don't wait to see if it worsens.
7. After initial stabilization with intravenous fluids, which intervention is the most appropriate and definitive management for this patient's condition?
   Answer: Arrangement for emergent hemodialysis. This patient presents with severe lithium toxicity (level >2.5 mEq/L) complicated by significant neurologic symptoms (seizures, altered mental status) and pre-existing renal insufficiency. Hemodialysis is the most effective method for rapidly clearing lithium from the body and is indicated in cases of severe toxicity, especially when accompanied by neurologic compromise or renal failure. Forced diuresis is ineffective and potentially harmful. Sodium polystyrene sulfonate is for hyperkalemia, and whole bowel irrigation is for acute ingestions of extended-release products, not established systemic toxicity.
8. Which laboratory test should be prioritized to investigate a likely metabolic cause of the patient's encephalopathy related to their mood stabilizer?
   Answer: Serum ammonia level. Divalproex can cause hyperammonemic encephalopathy even in the absence of significant liver dysfunction. This is particularly true in elderly patients or those with underlying urea cycle defects. The symptoms of confusion, lethargy, and asterixis are classic for this condition. While checking a drug level is reasonable, the encephalopathy can occur even with therapeutic divalproex levels. Therefore, checking a serum ammonia level is the key diagnostic step. Calcium and thyroid abnormalities are not characteristic adverse effects of divalproex.
9. When counseling the patient on the teratogenic risks of her current medication, it is most important to emphasize the significantly increased risk for which of the following fetal abnormalities?
   Answer: Neural tube defects such as spina bifida. Valproic acid is a potent teratogen with a well-established, dose-dependent risk of causing major congenital malformations. The most significant and characteristic risk is for neural tube defects (e.g., spina bifida, anencephaly), with an incidence many times higher than in the general population. Ebstein's anomaly is classically associated with first-trimester lithium exposure. Congenital hypothyroidism is a risk with maternal hypothyroidism, which can be caused by lithium. Limb malformations are less specific to valproate.
10. Which finding, directly attributable to the medication, would be most likely to increase the patient's risk of surgical bleeding and potentially delay the procedure?
    Answer: Dose-dependent thrombocytopenia. Divalproex can cause a dose-dependent thrombocytopenia (low platelet count). Platelets are essential for primary hemostasis and clotting. A significantly low platelet count would increase the risk of perioperative bleeding and would be a major concern for the surgical and anesthesia teams, potentially leading to postponement of the surgery until the count recovers after dose reduction or discontinuation. While the other options are known effects of divalproex, they do not directly impact the risk of surgical bleeding to the same degree as thrombocytopenia.
11. What is the expected impact of adding carbamazepine on the patient's lamotrigine therapy, and what adjustment is likely needed?
    Answer: Carbamazepine will induce lamotrigine metabolism, requiring an increase in the lamotrigine dose. Carbamazepine is a potent inducer of UGT enzymes, which are responsible for glucuronidating and eliminating lamotrigine. The addition of carbamazepine can decrease lamotrigine concentrations by approximately 40-50%. To maintain therapeutic efficacy, the dose of lamotrigine often needs to be increased, sometimes doubled, when co-administered with an enzyme inducer like carbamazepine. This is the opposite of the interaction with valproate, an enzyme inhibitor.
12. Which of the following is the most critical screening to perform before initiating therapy to mitigate the risk of a potentially fatal cutaneous reaction?
    Answer: HLA-B*1502 allele testing to screen for genetic risk of Stevens-Johnson syndrome. The presence of the HLA-B*1502 allele, which is more common in people of Asian descent, is strongly associated with an increased risk of developing carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The FDA recommends screening for this allele in this patient population before initiating carbamazepine. While monitoring CBC and sodium are important during therapy, the genetic screening is the most critical step before initiation to prevent this specific life-threatening reaction.
13. According to standard clinical practice guidelines for a stable patient on long-term lithium, what is the most appropriate frequency for monitoring serum creatinine and TSH?
    Answer: Every 6 to 12 months. When you encounter questions about lithium monitoring, think about balancing patient safety with practical clinical care. Lithium has a narrow therapeutic window and can cause serious long-term effects, particularly on kidney and thyroid function, which requires systematic monitoring even in stable patients. For stable patients on long-term lithium therapy, clinical guidelines recommend monitoring serum creatinine and TSH every 6 to 12 months. This frequency reflects the chronic, gradual nature of lithium's potential adverse effects on renal and thyroid function. Since this patient has been stable for three years with normal lab values six months ago, continuing this established monitoring interval is appropriate and follows evidence-based practice standards. Let's examine why the other options miss the mark. Option B (every 3 months) represents monitoring frequency typically reserved for patients who are newly initiated on lithium, have unstable levels, or show signs of organ dysfunction. Option C (monthly monitoring) is excessive for stable patients and typically used only during initial dose titration or when managing toxicity concerns. Option D (monitoring only with symptoms) is dangerous because both nephrotoxicity and thyroid dysfunction can develop insidiously without obvious clinical symptoms until significant damage has occurred. Remember that lithium monitoring follows a risk-stratified approach: more frequent monitoring during initiation and dose changes, then standard intervals (6-12 months) for stable patients. The key is understanding that "stable" doesn't mean "no monitoring needed" – it means you can follow routine surveillance rather than intensive monitoring protocols.
14. Which of the following is the most likely explanation for the patient's current presentation?
    Answer: The over-the-counter NSAID has reduced renal prostaglandin synthesis, leading to decreased lithium clearance. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the synthesis of renal prostaglandins, which are involved in maintaining renal blood flow and glomerular filtration rate. This reduction can lead to decreased renal clearance of lithium, causing the drug to accumulate and reach toxic levels. The patient's symptoms are classic signs of lithium toxicity. Serotonin syndrome has some overlapping symptoms but is an incorrect mechanism. Tolerance would lead to a need for a higher dose, not toxicity at a previously stable dose. A manic episode is less likely to present with these specific neurological signs of toxicity.
15. What is the most appropriate next step in management?
    Answer: Hold the next dose, decrease the total daily dose, and recheck the level in one week. A lithium level of 1.4 mEq/L is in the mild toxicity range. While the patient's symptoms are not severe, the elevated level is the root cause and must be addressed. The most appropriate management is to hold a dose or two and then restart at a lower total daily dose to bring the level back into the therapeutic range. Adding a beta-blocker treats the symptomatic tremor but ignores the underlying supratherapeutic level. Immediate discontinuation and admission are not necessary for mild, asymptomatic toxicity. While an EKG and BMP are not unreasonable, the primary action is dose adjustment.
16. These findings are most consistent with lithium-induced damage to which part of the nephron, leading to the patient's condition?
    Answer: The collecting ducts, causing resistance to antidiuretic hormone (ADH). The clinical picture is classic for nephrogenic diabetes insipidus (NDI), a well-known long-term complication of lithium therapy. Lithium enters the principal cells of the collecting ducts and interferes with the ADH signaling cascade, primarily by downregulating aquaporin-2 water channels. This makes the collecting ducts resistant to the effects of ADH, impairing water reabsorption and leading to the excretion of large volumes of dilute urine. The lack of response to desmopressin (an ADH analog) confirms the nephrogenic (renal) origin rather than a central (pituitary) cause.
17. Which agent is generally considered less effective for treating acute mania and is more indicated for maintenance therapy and bipolar depression?
    Answer: Lamotrigine. While lithium, divalproex, and carbamazepine all have established efficacy in the treatment of acute mania, lamotrigine does not. Lamotrigine's primary utility in bipolar disorder is for the prevention of depressive episodes (maintenance therapy) and, to some extent, the treatment of acute bipolar depression. The slow titration required to prevent SJS also makes it impractical for controlling acute manic symptoms.
18. Given the patient's significant renal impairment, which of the following mood stabilizers should be avoided?
    Answer: Lithium. Lithium is almost exclusively eliminated by the kidneys, with its clearance being directly proportional to the glomerular filtration rate (GFR). In a patient with pre-existing CKD, lithium clearance is significantly impaired, leading to a very high risk of accumulation and toxicity, even at standard doses. Divalproex, lamotrigine, and carbamazepine are primarily metabolized by the liver and are therefore much safer options in patients with renal disease.

Start this quiz